10 likes | 45 Views
MPN MLPA screening analysis is a comprehensive testing to identify panel gene hotspot mutations (JAK2, MPL & CALR) associated with the myeloproliferative neoplasms including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Mutation analysis helps to differentiate reactive conditions from MPNs, may provide prognostic information, and may help distinguish ET and PMF from PV. DDRC SRL Diagnostic network in Kerala offers MPN MLPA Screening Panel test for the customers.
E N D
Molecular Genetics MPN MLPA Screening Panel Test Code: Test indication: MPN MLPA JAK2 EXON 14 EXON 12 CALR and MPL Suspected myeloproliferative neoplasms. Detects JAK 2 (Exon 14 and 12), CALR and MPL mutations in peripheral blood or bone marrow. MLPA 3 working days 5 ml EDTA Whole Blood or EDTA Bone Marrow Methodology: TAT: Sample type : Sample storage and Transportation: Recommendation: Sample unacceptable criteria: Genes Tested: Sample to be stored and transported in 2 to 8 degree temperature Kindly include relavent clinical histroy and indications Sample collected in other than EDTA, samples not maintained in above recommeded temperature conditions, Clotted or hemolyzed specimen. JAK2, MPL and CALR The current WHO diagnostic criteria for classic MPNs include presence of JAK2, CALR or MPL mutations Other assays Available: Real time PCR based EGFR mutation detection (Liquid Biopsy is also performed in Plasma) BCRABL (Major), KRAS, BRAF, JAK2 (Exon 14). NGS based Cancer Hotspot assay covering almost all cancer types (Hotspots – Most frequent mutations) Corporate Office & Referral Laboratory, DDRC SRL Towers, Panampilly Nagar, Kochi-682 036 Ph: +91 484 2318222, 2318223 email: info@ddrcsrl.com www.ddrcsrl.com 94963 98078 85906 01094